GLP-1 Drugs in Teens: The Nutrition Gap

A study published in the journal Childhood Obesity on 17 September 2026 looked at what happens to the diets of young patients after they start a GLP-1 receptor agonist, the drug class that includes semaglutide (sold as Wegovy for weight management and Ozempic for type-2 diabetes) and works by mimicking a gut hormone that reduces appetite^[1]. Researchers led by Kerr and colleagues at Abbott Nutrition tracked 2,031 patients aged 10 to 17 who filled a first prescription for a GLP-1 drug between 2017 and 2022, using insurance claims records rather than clinical charts. Within one year, 16.88% of those patients were diagnosed with at least one nutritional deficiency, and only 23.3% had a nutrition therapy or counseling visit, meaning an appointment with a dietitian or similar specialist, within 180 days of starting treatment.

The numbers behind the finding

Vitamin D deficiency was the single most common finding, showing up in 12.4% of the group within the first year^[1]. That is a meaningful share of teenagers who are also, by definition, still building bone density and the mineral reserves that depend on adequate vitamin D and calcium status.

The nutrition-counseling numbers run the opposite direction from what you might expect. Patients who did see a dietitian within 180 days had a higher deficiency rate, 23.2%, than patients who did not, 14.8%^[1]. Kerr and colleagues read this as a marker of severity rather than a sign that counseling causes harm. Clinicians appear to be referring the patients who already look nutritionally at-risk, not creating the risk by referring them.

Why the prescribing label stays quiet on nutrition

Semaglutide's pediatric indication, marketed as Wegovy for patients aged 12 and older with obesity, is documented in detail on the FDA-approved prescribing label. The label sets out the approved maintenance dose, either 2.4 mg weekly or 1.7 mg if the higher dose is not tolerated, and the adverse-event data from the pediatric trial^[2]. What the label does not include is a dedicated section on nutrition monitoring, growth surveillance, or when to refer a patient for dietitian support. That gap is close to what the Childhood Obesity study is pointing at: the prescribing information tells a clinician how to dose the drug, not how to watch a still-growing patient's nutrient intake while they are on it.

The broader pediatric literature has a similar gap. A 2026 systematic review in the journal Nutrients examined 15 trials of GLP-1 and dual GIP/GLP-1 therapy in 1,448 patients aged 6 to 19 and found that the diet and lifestyle support delivered alongside the drug varied enormously, from structured programs with individualized dietary counseling and family involvement down to general advice with no formal behavior-change support^[3]. None of the trials the reviewers examined used a standardized way of measuring what patients were actually eating, which means the field does not yet have a clear picture of how GLP-1 therapy changes a growing child's diet, only that it changes their weight.

What the appetite effect looks like in trial data

The clearest pediatric efficacy data come from STEP TEENS, the trial that supported Wegovy's approval in patients aged 12 to 17. Over 68 weeks, patients on semaglutide had a mean BMI reduction of 16.1%, compared with 0.6% on placebo, and 73% of the semaglutide group lost at least 5% of their body weight, versus 18% on placebo^[4]. Gastrointestinal side effects, most commonly nausea, were also more common on the drug (62% versus 42% on placebo), and 4% of the semaglutide group developed gallstones during the trial, against none on placebo.

None of that is a criticism of the drug's effectiveness. It is a description of how it works. Semaglutide slows how fast food leaves the stomach and acts on appetite centers in the brain, so patients eat less and feel full sooner^[4]. For an adult, that mechanism is the entire point. For a child or teenager who is still growing, eating meaningfully less food for a year or more raises the practical question of whether they are still getting enough protein, calcium, iron and vitamin D to support normal development, not just enough calories to lose weight.

What this study does not show

The Kerr study is a retrospective look at insurance claims, not a clinical trial, and it carries the limitations that format brings. Claims data record diagnosis codes and billed visits, not what a patient actually ate, so the researchers could not see food records or supplement use. The design also cannot separate cause from detection: a teenager who sees a doctor more often while starting a new medication is more likely to get blood work that catches a deficiency that might otherwise go undiagnosed, one that could have existed before the prescription was ever written.

Some of that baseline risk is already well established. A 2023 narrative review in the journal Children found that roughly one in two children with severe obesity were vitamin D deficient even before any GLP-1 treatment enters the picture, alongside elevated rates of iron and vitamin B12 deficiency^[5]. That does not make the Kerr findings irrelevant. It means the fair reading is that GLP-1 therapy is layering an appetite-suppressing drug onto a population that already carries elevated nutritional risk, and the counseling rate the study found, 23.3% within 180 days, suggests that layer is not being actively managed for most patients.

What this means for families and clinicians

None of this is a reason to avoid semaglutide or another GLP-1 drug for an adolescent who has been prescribed one. STEP TEENS reported a real and substantial weight-loss benefit for semaglutide^[4], and a family's clinician weighs that benefit against the risks for that specific patient. It is a reason to raise the specific question the Kerr study points to: whether a nutrition therapy or counseling visit, plus baseline and follow-up bloodwork for vitamin D and other micronutrients, is part of the plan. The specialists best placed to manage that monitoring are a pediatrician, endocrinologist or registered dietitian working with the family, not a self-directed supplement routine.

If you are a parent or caregiver navigating this, the conversation to have with your child's care team is straightforward. Ask what nutrition monitoring is built into the treatment plan, and ask it at the first visit, not after a deficiency shows up on a lab test.